The pharmacologic management of multiple myeloma in older adults

References

• Antonio Palumbo KA. Multiple myeloma. N Engl J Med. 2011;364:1046–1060.
   PubMed Web of Science ®Google Scholar
• SEER. Cancer Stat Facts: myeloma. National Cancer Institute cited; Available from: https://seer.cancer.gov/statfacts/html/mulmy.html
   Google Scholar
• Clegg A, Young J, Iliffe S, et al. Frailty in elderly people. Lancet. 2013;381(9868):752–762.
   PubMed Web of Science ®Google Scholar
• Mathur P, Thanendrarajan S, Paydak H, et al. Cardiovascular complications of multiple myeloma in the elderly. Expert Rev Cardiovasc Ther. 2017 Dec;15(12):933–943.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Terpos E, Gavriatopoulou M, et al. Myeloma in the octogenarians: disease characteristics and clinical outcomes in the era of modern anti-myeloma therapy. Blood. 2014 Dec 6;124:21.
   Google Scholar
• Diamond E, Lahoud OB, Landau H. Managing multiple myeloma in elderly patients. Leuk Lymphoma. 2017 Aug;28:1–12.
   Google Scholar
• Rosko A, Giralt S, Mateos M-V, et al. Myeloma in elderly patients: when less is more and more is more. ASCO Educ Book. 2017;37:575–585.
   Google Scholar
• Palumbo A, Mateos MV, Bringhen S, et al. Practical management of adverse events in multiple myeloma: can therapy be attenuated in older patients? Blood Rev. 2011 Jul;25(4):181–191.
   PubMed Web of Science ®Google Scholar
• Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008 Mar 1;111(5):2516–2520.
   PubMed Web of Science ®Google Scholar
• Brenner H, Gondos A, Pulte D. Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood. 2008 Mar 1;111(5):2521–2526.
   PubMed Web of Science ®Google Scholar
• Larocca A, Palumbo A. Optimizing treatment for elderly patients with newly diagnosed multiple myeloma: a personalized approach. J Clin Oncol. 2016 Oct 20;34(30):3600–3604.
   PubMed Web of Science ®Google Scholar
• Wildes TM, Rosko A, Tuchman SA. Multiple myeloma in the older adult: better prospects, more challenges. J Clin Oncol. 2014 Aug 20;32(24):2531–2540.
   PubMed Web of Science ®Google Scholar
• Kelly CM, Shahrokni A. Moving beyond karnofsky and ECOG performance status assessments with new technologies. J Oncol. 2016;2016:6186543.
   PubMed Web of Science ®Google Scholar
• Mohile SG, Dale W, Somerfield MR, et al. Practical assessment and management of vulnerabilities in older patients receiving chemotherapy: ASCO guideline for geriatric oncology. J Clin Oncol. 2018 Aug 1;36(22):2326–2347.
   PubMed Web of Science ®Google Scholar
• Hurria A. Geriatric assessment in oncology practice. J Am Geriatr Soc. 2009 Nov;57(Suppl 2):S246–9.
   PubMedGoogle Scholar
• Cohen HJ. Evolution of geriatric assessment in oncology. J Oncol Pract. 2018 Feb;14(2):95–96.
   PubMed Web of Science ®Google Scholar
• Magnuson A, Dale W, Mohile S. Models of care in geriatric oncology. Curr Geriatr Rep. 2014 Sep;3(3):182–189.
   PubMedGoogle Scholar
• Mohile SG, Velarde C, Hurria A, et al. Geriatric assessment-guided care processes for older adults: a delphi consensus of geriatric oncology experts. J Natl Compr Canc Netw. 2015 Sep;13(9):1120–1130.
   PubMed Web of Science ®Google Scholar
• Zhang X, Meng X, Chen Y, et al. The biology of aging and cancer: frailty, inflammation, and immunity. Cancer J. 2017 July/Aug;23(4):201–205.
   PubMed Web of Science ®Google Scholar
• Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001 Mar;56(3):M146–56.
   PubMed Web of Science ®Google Scholar
• Ferrat E, Paillaud E, Caillet P, et al. Performance of four frailty classifications in older patients with cancer: prospective elderly cancer patients cohort study. J Clin Oncol. 2017 Mar;35(7):766–777.
   PubMed Web of Science ®Google Scholar
• Li S, Natwick T, Liu J, et al. Mortality by frailty status as defined by a claims-based disability status in elderly patients newly diagnosed with multiple myeloma in the United States. Clin Lymphoma Myeloma Leukemia. 2017;17(1):e52–e53.
   PubMedGoogle Scholar
• Nathwani N, Mohile SG, Lipe B, et al. Integrating a touchscreen-based brief geriatric assessment in older adults with multiple myeloma. Am Soc Clin Oncol. 2017.
   Google Scholar
• Schutz N, Smietniansky M, Fantl D, et al. Frailty and mortality in elderly patients with multiple myeloma. Haematologica. 2017;518. ferrata storti foundation via giuseppe belli 4, 27100 pavia, italY; 2017. Available from: https://learningcenter.ehaweb.org/eha/2017/22nd/181040/natalia.schutz.frailty.and.mortality.in.elderly.patients.with.multiple.myeloma.html?f=menu%3D14%2Abrowseby%3D8%2Asortby%3D2%2Amedia%3D2%2Aspeaker%3D570625
   Google Scholar
• Palumbo A, Bringhen S, Mateos MV, et al. Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an international myeloma working group report. Blood. 2015 Mar 26;125(13):2068–2074.
   PubMed Web of Science ®Google Scholar
• Engelhardt M, Domm A-S, Dold SM, et al. A concise revised myeloma comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients. Haematologica. 2017 May;102(5):910–921.
   Google Scholar
• Fiala MA, Guerard EJ, Schroeder MA, et al. Development and validation of a medicare health outcomes survey (MHOS) frailty index in multiple myeloma (MM). J clin oncol. 2017 May 20;35.
   Web of Science ®Google Scholar
• Wildes TM, Tuchman SA, Depp B, et al. Geriatric assessment (GA) and eligibility for autologous stem cell transplant (ASCT) in older adults with newly diagnosed multiple myeloma (MM). J clin oncol. 2015 May 20;33:15.
   Web of Science ®Google Scholar
• Rosko AE, Huang Y, Benson DM, et al. Use of a comprehensive frailty assessment to predict morbidity in patients with multiple myeloma undergoing transplant. J Geriatr Oncol. 2018 Jul 5. pii: S1879-4068(18)30157-7. doi: 10.1016/j.jgo.2018.05.015.
   Web of Science ®Google Scholar
• Koll TT, Rosko AE. Frailty in hematologic malignancy. Curr Hematol Malig Rep. 2018 Jun;13(3):143–154.
   PubMed Web of Science ®Google Scholar
• Abel GA, Klepin HD. Frailty and the management of hematologic malignancies. Blood. 2018 Feb 1;131(5):515–524.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Jacobus S, Callander NS. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial (vol 11, pg 29, 2010). Lancet Oncol. 2010 Jan;11(1):14.
   Web of Science ®Google Scholar
• Alexanian R, Haut A, Khan AU, et al. Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens. JAMA. 1969 Jun 02;208(9):1680–1685.
   PubMed Web of Science ®Google Scholar
• Popat U, Saliba R, Thandi R, et al. Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma. Biol Blood Marrow Transplant. 2009 Jun;15(6):718–723.
   PubMed Web of Science ®Google Scholar
• Jagannath S, Abonour R, Durie BGM, et al. Heterogeneity of second-line treatment for patients with multiple myeloma in the connect MM registry (2010–2016). Clin Lymphoma Myeloma Leuk. 2018 Jul;18(7):480–485.
   Google Scholar
• Hernandez JM, Garcia-Sanz R, Golvano E, et al. Randomized comparison of dexamethasone combined with melphalan versus melphalan with prednisone in the treatment of elderly patients with multiple myeloma. Br J Haematol. 2004 Oct;127(2):159–164.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Bringhen S, Caravita T, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet. 2006 Mar 11;367(9513):825–831.
   PubMed Web of Science ®Google Scholar
• Mateos MV, San Miguel JF. How should we treat newly diagnosed multiple myeloma patients? Hematol Am Soc Hematol Educ Program. 2013;2013:488–495.
   PubMedGoogle Scholar
• Mateos MV, Dimopoulos MA, Cavo M, et al. Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma. N Engl J Med. 2018 Feb 8;378(6):518–528.
   PubMed Web of Science ®Google Scholar
• Niesvizky R, Flinn IW, Rifkin R, et al. Community-based phase IIIB trial of three UPFRONT bortezomib-based myeloma regimens. J Clin Oncol. 2015 Nov 20;33(33):3921–3929.
   PubMed Web of Science ®Google Scholar
• Berenson JR, Cartmell A, Bessudo A, et al. CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma. Blood. 2016 Jun 30;127(26):3360–3368.
   PubMed Web of Science ®Google Scholar
• Moreau P, Mateos M-V, Berenson JR, et al. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study. Lancet Oncol. 2018 Jul;19(7):953–964.
   PubMedGoogle Scholar
• Mikhael J. Management of carfilzomib-associated cardiac adverse events. Clin Lymphoma Myeloma Leuk. 2016 May;16(5):241–245.
   PubMed Web of Science ®Google Scholar
• Jakubowiak AJ, Dytfeld D, Griffith KA, et al. A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. Blood. 2012 Aug 30;120(9):1801–1809.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Jacobus S, Callander NS, et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol. 2010;11(1):29–37.
   PubMed Web of Science ®Google Scholar
• Touzeau C, Blin N, Clavert A, et al. Efficacy of lenalidomide plus dexamethasone in patients older than 75 years with relapsed multiple myeloma. Leuk Lymphoma. 2012 Jul;53(7):1318–1320.
   PubMed Web of Science ®Google Scholar
• Leleu X, Attal M, Arnulf B, et al. Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: intergroupe francophone du myelome 2009–02. Blood. 2013 Mar 14;121(11):1968–1975.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Waage A, Hulin C, et al. Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials. Haematologica. 2013 Jan;98(1):87–94.
   PubMed Web of Science ®Google Scholar
• Facon T, Mary JY, Hulin C, et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99?06): a randomised trial. Lancet. 2007;370(9594):1209–1218.
   PubMed Web of Science ®Google Scholar
• Celgene. Revlimid package insert. 2017 [cited 2018 June]. Available from: http://media.celgene.com/content/uploads/revlimid-pi.pdf
   Google Scholar
• Zweegman S, van der Holt B, Mellqvist UH, et al. Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma. Blood. 2016 Mar 03;127(9):1109–1116.
   PubMed Web of Science ®Google Scholar
• Gay F, Hayman SR, Lacy MQ, et al. Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients. Blood. 2010 Feb 18;115(7):1343–1350.
   PubMed Web of Science ®Google Scholar
• Benboubker L, Dimopoulos MA, Dispenzieri A, et al. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med. 2014 Sep 04;371(10):906–917.
   PubMed Web of Science ®Google Scholar
• Durie BGM, Hoering A, Abidi MH, et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet. 2017 Feb 4;389(10068):519–527.
   PubMed Web of Science ®Google Scholar
• Stewart AK, Rajkumar SV, Dimopoulos MA, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015 Jan 8;372(2):142–152.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Oriol A, Nahi H, et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016 Oct 6;375(14):1319–1331.
   PubMed Web of Science ®Google Scholar
• Lonial S, Dimopoulos M, Palumbo A, et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med. 2015 Aug 13;373(7):621–631.
   PubMed Web of Science ®Google Scholar
• McCarthy PL, Owzar K, Hofmeister CC, et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012 May 10;366(19):1770–1781.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Bringhen S, Kumar SK, et al. Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. Lancet Oncol. 2014;15(3):333–342.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Rajkumar SV, Ma D, et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia. 2008 Feb;22(2):414–423.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Siegel DS, Vij R, et al. Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. Blood. 2014 Mar 20;123(12):1826–1832.
   PubMed Web of Science ®Google Scholar
• Miguel JS, Weisel K, Moreau P, et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013;14(11):1055–1066.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Palumbo A, Corradini P, et al. Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma. Blood. 2016 Jul 28;128(4):497–503.
   PubMed Web of Science ®Google Scholar
• Celgene. Pomalyst package insert. 2018 May [cited 2018 Jun]. Available from: http://media.celgene.com/content/uploads/pomalyst-pi.pdf
   Google Scholar
• Scalzulli E, Grammatico S, Vozella F, et al. Proteasome inhibitors for the treatment of multiple myeloma. Expert Opin Pharmacother. 2018 Mar;19(4):375–386.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Bringhen S, Rossi D, et al. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. J Clin Oncol. 2010 Dec 1;28(34):5101–5109.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Weller E, Lonial S, et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood. 2010 Aug 5;116(5):679–686.
   PubMed Web of Science ®Google Scholar
• Mateos MV, Oriol A, Martinez-Lopez J, et al. Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial. Blood. 2012 Sep 27;120(13):2581–2588.
   PubMed Web of Science ®Google Scholar
• San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008;359:906–917.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed mulitple myeloma. N Engl J Med. 2005;352(24):2487–2498.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Terpos E, Chanan-Khan A, et al. Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the international myeloma working group. J Clin Oncol. 2010 Nov 20;28(33):4976–4984.
   PubMed Web of Science ®Google Scholar
• San Miguel JF, Schlag R, Khuageva NK, et al. Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma. J Clin Oncol. 2013 Feb 1;31(4):448–455.
   PubMed Web of Science ®Google Scholar
• Jimenez-Zepeda VH, Venner CP, Belch A, et al. Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) compared to Lenalidomide and Dexamethasone (LD) for the treatment of non-transplant eligible multiple myeloma. Blood. 2015 Dec 3;126:23.
   Google Scholar
• Kumar S, Flinn IW, Richardson PG, et al. Novel three- and four-drug combination regimens of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide, for previously untreated multiple myeloma: results from the multi-center, randomized, phase 2 EVOLUTION study. Blood. 2010 Nov 19;116(21):273.
   Google Scholar
• Mateos M-V, Oriol A, Martínez-López J, et al. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial. Lancet Oncol. 2010;11(10):934–941.
   PubMed Web of Science ®Google Scholar
• Sonneveld P, Schmidt-Wolf IG, van der Holt B, et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/GMMG-HD4 trial. J Clin Oncol. 2012 Aug 20;30(24):2946–2955.
   PubMed Web of Science ®Google Scholar
• Sengsayadeth S, Malard F, Savani BN, et al. Posttransplant maintenance therapy in multiple myeloma: the changing landscape. Blood Cancer J. 2017 Mar 24;7(3):e545.
   PubMedGoogle Scholar
• Dimopoulos MA, Moreau P, Palumbo A, et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol. 2016;17(1):27–38.
   PubMed Web of Science ®Google Scholar
• Bringhen S, Petrucci MT, Larocca A, et al. Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study. Blood. 2014 Jul 3;124(1):63–69.
   PubMed Web of Science ®Google Scholar
• Shah JJ, Stadtmauer EA, Abonour R, et al. Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma. Blood. 2015 Nov 12;126(20):2284–2290.
   PubMed Web of Science ®Google Scholar
• AMGEN. Carfilzomib Package Insert. 2018 [cited Aug 5]. Available from: https://pi.amgen.com/~/media/amgen/repositorysites/pi-amgen-com/kyprolis/kyprolis_pi.pdf
   Google Scholar
• Lataifeh AR, Nusair A. Fatal pulmonary toxicity due to carfilzomib (Kyprolis). J Oncol Pharm Pract. 2016 Oct;22(5):720–724.
   PubMed Web of Science ®Google Scholar
• Bringhen S, Mina R, Cafro AM, et al. Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study. Leukemia. 2018 Aug;32(8):1803–1807.
   Web of Science ®Google Scholar
• Takeda. Ixazomib package insert. [ cited 2018 June]. Available from: https://www.ninlarohcp.com/pdf/prescribing-information.pdf
   Google Scholar
• Moreau P, Masszi T, Grzasko N, et al. Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016 Apr 28;374(17):1621–1634.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Morgan GJ, Rajkumar SV, et al. Two phase 3 studies of the oral proteasome inhibitor (PI) ixazomib for multiple myeloma (MM) in the maintenance setting: TOURMALINE-MM3, and-MM4. J clin oncol. 2016 May 20;34:15.
   Web of Science ®Google Scholar
• Auner HW, Garderet L, Kroger N. Autologous haematopoietic cell transplantation in elderly patients with multiple myeloma. Br J Haematol. 2015 Nov;171(4):453–462.
   PubMed Web of Science ®Google Scholar
• Al-Hamadani M, Hashmi SK, Go RS. Use of autologous hematopoietic cell transplantation as initial therapy in multiple myeloma and the impact of socio-geo-demographic factors in the era of novel agents. Am J Hematol. 2014 Aug;89(8):825–830.
   PubMed Web of Science ®Google Scholar
• Auner HW, Szydlo R, Hoek J, et al. Trends in autologous hematopoietic cell transplantation for multiple myeloma in Europe: increased use and improved outcomes in elderly patients in recent years. Bone Marrow Transplant. 2015 Feb;50(2):209–215.
   PubMed Web of Science ®Google Scholar
• D’Souza AFC, D’Souza A, Fretham C Current uses and outcomes of hematopoietic cell transplantation (HCT): CIBMTR Summary Slides, 2017 [cited 2019 Jan]. Available from: http://www.cibmtr.org
   Google Scholar
• Facon T, Mary JY, Hulin C, et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet. 2007 Oct 06;370(9594):1209–1218.
   PubMed Web of Science ®Google Scholar
• Garderet L, Beohou E, Caillot D, et al. Upfront autologous stem cell transplantation for newly diagnosed elderly multiple myeloma patients: a prospective multicenter study. Haematologica. 2016 Nov;101(11):1390–1397.
   PubMed Web of Science ®Google Scholar
• Sharma M, Zhang MJ, Zhong X, et al. Older patients with myeloma derive similar benefit from autologous transplantation. Biology of blood and marrow transplantation. J Am Soc Blood Marrow Transplantation. 2014 Nov;20(11):1796–1803.
   PubMed Web of Science ®Google Scholar
• Wildes TM, Finney JD, Fiala M, et al. High-dose therapy and autologous stem cell transplant in older adults with multiple myeloma. Bone Marrow Transplant. 2015 Aug;50(8):1075–1082.
   PubMed Web of Science ®Google Scholar
• Sánchez-Ortega I, Basak GW, Beohou E, et al. Autologous hematopoietic cell transplantation in elderly patients aged 65 and older: a retrospective analysis by the complications and quality of life working party of the EBMT American Society of Hematology. Blood. 2016;128(22):678.
   Google Scholar
• Gertz MA, Lacy MQ, Dispenzieri A, et al. Impact of age and serum creatinine value on outcome after autologous blood stem cell transplantation for patients with multiple myeloma. Bone Marrow Transplant. 2007 May;39(10):605–611.
   PubMed Web of Science ®Google Scholar
• Siegel DS, Desikan KR, Mehta J, et al. Age is not a prognostic variable with autotransplants for multiple myeloma. Blood. 1999 Jan 01;93(1):51–54.
   PubMed Web of Science ®Google Scholar
• Kumar SK, Dingli D, Lacy MQ, et al. Autologous stem cell transplantation in patients of 70 years and older with multiple myeloma: results from a matched pair analysis. Am J Hematol. 2008 Aug;83(8):614–617.
   PubMed Web of Science ®Google Scholar
• Merz M, Neben K, Raab MS, et al. Autologous stem cell transplantation for elderly patients with newly diagnosed multiple myeloma in the era of novel agents. Ann Oncol. 2014 Jan;25(1):189–195.
   PubMed Web of Science ®Google Scholar
• Bashir Q, Shah N, Parmar S, et al. Feasibility of autologous hematopoietic stem cell transplant in patients aged >/=70 years with multiple myeloma. Leuk Lymphoma. 2012 Jan;53(1):118–122.
   PubMed Web of Science ®Google Scholar
• Huang LW, Bacon W, Cirrincione C, et al. Efficacy and safety of high-dose chemotherapy with autologous stem cell transplantation in senior versus younger adults with newly diagnosed multiple myeloma. Hematol Oncol. 2017 Dec;35(4):752–759.
   Web of Science ®Google Scholar
• Lokhorst HM, Plesner T, Laubach JP, et al. Targeting CD38 with daratumumab monotherapy in multiple myeloma. N Engl J Med. 2015 Sep 24;373(13):1207–1219.
   PubMed Web of Science ®Google Scholar
• Chari A, Suvannasankha A, Fay JW, et al. Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma. Blood. 2017 Aug 24;130(8):974–981.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Chanan-Khan A, Weisel K, et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med. 2016 Aug 25;375(8):754–766.
   PubMed Web of Science ®Google Scholar
• Chapuy CI, Aguad MD, Nicholson RT, et al. International validation of a dithiothreitol (DTT)-based method to resolve the daratumumab interference with blood compatibility testing. Transfusion. 2016 Dec;56(12):2964–2972.
   PubMed Web of Science ®Google Scholar
• Kumar S, Kaufman JL, Gasparetto C, et al. Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma. Blood. 2017 Nov 30;130(22):2401–2409.
   PubMed Web of Science ®Google Scholar
• Moreau P, Chanan-Khan A, Roberts AW, et al. Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM. Blood. 2017 Nov 30;130(22):2392–2400.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Sonneveld P, Schuster MW, et al. Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma. Br J Haematol. 2007 Jun;137(5):429–435.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Briemberg H, Jagannath S, et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol. 2006 Jul 1;24(19):3113–3120.
   PubMed Web of Science ®Google Scholar
• Bringhen S, Larocca A, Rossi D, et al. Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood. 2010 Dec 2;116(23):4745–4753.
   PubMed Web of Science ®Google Scholar
• O’Donnell EK, Laubach JP, Yee AJ, et al. A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma. Br J Haematol. 2018 Jul;182(2):222–230.
   Web of Science ®Google Scholar
• Moreau P, Pylypenko H, Grosicki S, et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol. 2011;12(5):431–440.
   PubMed Web of Science ®Google Scholar
• Waxman AJ, Clasen S, Hwang WT, et al. Carfilzomib-associated cardiovascular adverse events: a systematic review and meta-analysis. JAMA Oncol. 2018 Mar 8;4(3):e174519.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Roussou M, Gavriatopoulou M, et al. Cardiac and renal complications of carfilzomib in patients with multiple myeloma. Blood Adv. 2017 Feb 28;1(7):449–454.
   PubMed Web of Science ®Google Scholar
• Chanan-Khan A, Sonneveld P, Schuster MW, et al. Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study. J Clin Oncol. 2008 Oct 10;26(29):4784–4790.
   PubMed Web of Science ®Google Scholar
• Delforge M, Ludwig H. How I manage the toxicities of myeloma drugs. Blood. 2017 Apr 27;129(17):2359–2367.
   PubMed Web of Science ®Google Scholar
• Jung SH, Kang SJ, Jang HC, et al. Effect of levofloxacin prophylaxis for prevention of severe infections in multiple myeloma patients receiving bortezomib-containing regimens. Int J Hematol. 2014 Nov;100(5):473–477.
   PubMed Web of Science ®Google Scholar
• Drayson MT, Bowcock S, Planche T, et al. Tackling early morbidity and mortality in myeloma (TEAMM): assessing the benefit of antibiotic prophylaxis and its effect on healthcare associated infections in 977 patients. Blood Abstracts & Meeting Program. 2017;130(Suppl 1):903.
   Google Scholar
• Ueda M, Berger M, Gale RP, et al. Immunoglobulin therapy in hematologic neoplasms and after hematopoietic cell transplantation. Blood Rev. 2018 Mar;32(2):106–115.
   PubMed Web of Science ®Google Scholar
• Raanani P, Gafter-Gvili A, Paul M, et al. Immunoglobulin prophylaxis in chronic lymphocytic leukemia and multiple myeloma: systematic review and meta-analysis. Leukemia Lymphoma. 2009;50(5):764–772.
   PubMed Web of Science ®Google Scholar
• Raje N, Terpos E, Willenbacher W, et al. Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study. Lancet Oncol. 2018;19(3):370–381.
   PubMed Web of Science ®Google Scholar
• Anderson K, Ismaila N, Flynn P, et al. Role of bone-modifying agents in multiple myeloma: american society of clinical oncology clinical practice guideline update. J clin oncol. 2018;36(8):812–818.
   PubMed Web of Science ®Google Scholar
• Stadtmauer EA, Sullivan KM, Marty FM, et al. A phase 1/2 study of an adjuvanted varicella-zoster virus subunit vaccine in autologous hematopoietic cell transplant recipients. Blood. 2014 Nov 6;124(19):2921–2929.
   PubMed Web of Science ®Google Scholar
• Bailey DG, Malcolm J, Arnold O, et al. Grapefruit juice-drug interactions. Br J Clin Pharmacol. 1998 Aug;46(2):101–110.
   PubMed Web of Science ®Google Scholar
• Perrone G, Hideshima T, Ikeda H, et al. Ascorbic acid inhibits antitumor activity of bortezomib in vivo. Leukemia. 2009 Sep;23(9):1679–1686.
   PubMed Web of Science ®Google Scholar
• Golden EB, Lam PY, Kardosh A, et al. Green tea polyphenols block the anticancer effects of bortezomib and other boronic acid-based proteasome inhibitors. Blood. 2009 Jun 4;113(23):5927–5937.
   PubMed Web of Science ®Google Scholar
• Danhof S, Hudecek M, Smith EL. CARs and other T cell therapies for MM: the clinical experience. Best Pract Res Clin Haematol. 2018 Jun;31(2):147–157.
   PubMed Web of Science ®Google Scholar
• Sobh M, Michallet M, Gahrton G, et al. Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years A Study by the EBMT Chronic Malignancies Working Party. Leukemia. 2016 Oct;30(10):2047–2054.
   PubMed Web of Science ®Google Scholar
• Ali SA, Shi V, Maric I, et al. T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma. Blood. 2016 Sep 29;128(13):1688–1700.
   PubMed Web of Science ®Google Scholar
• Cavo M, Terpos E, Nanni C, et al. Role of F-18-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the international myeloma working group. Lancet Oncol. 2017 Apr;18(4):E206–E17.
   PubMed Web of Science ®Google Scholar
• Nanni C, Versari A, Chauvie S, et al. Interpretation criteria for FDG PET/CT in multiple myeloma (IMPeTUs): final results. IMPeTUs (Italian myeloma criteria for PET USe). Eur J Nucl Med Mol I. 2018 May;45(5):712–719.
   PubMed Web of Science ®Google Scholar
• Paiva B, van Dongen JJM, Orfao A. New criteria for response assessment: role of minimal residual disease in multiple myeloma. Blood. 2015 May 14;125(20):3059–3068.
   PubMed Web of Science ®Google Scholar
• Paiva B, Puig N, Garcia-Sanz R, et al. Is this the time to introduce minimal residual disease in multiple myeloma clinical practice? Clin Cancer Res. 2015 May 1;21(9):2001–2008.
   PubMed Web of Science ®Google Scholar
• MacEwan JP, Batt K, Yin W, et al. Economic burden of multiple myeloma among patients in successive lines of therapy in the United States. Leuk Lymphoma. 2018 Apr;59(4):941–949.
   PubMed Web of Science ®Google Scholar
• Phase 2b STORM Data Evaluating Selinexor in Patients with Penta-Refractory Multiple Myeloma Presented at the Society of Hematologic Oncology 2018 Annual Meeting. Society of Hematologic Oncology 2018 Annual Meeting: Karyopharm Therapeutics Inc. 2018.
   Google Scholar
• Cho SF, Anderson KC, Tai YT. Targeting B Cell Maturation Antigen (BCMA) in multiple myeloma: potential uses of BCMA-based immunotherapy. Front Immunol. 2018;9:1821.
   PubMed Web of Science ®Google Scholar
• Paul B, Kang S, Zheng Z, et al. The challenges of checkpoint inhibition in the treatment of multiple myeloma. Cell Immunol. 2018;334:87–98.
   PubMed Web of Science ®Google Scholar
• FDA alerts healthcare professionals and oncology clinical investigators about tow clinical trials on hold evaluating KEYTRUDA (R) (pembrolizumab) in patients with multiple myeloma. 2017 August 31 [cited 2019 Jan 4]. Available from: https://www.fda.gov/Drugs/DrugSafety/ucm574305.htm
   Google Scholar
• Harousseau JL, Attal M, Avet-Loiseau H, et al. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. J Clin Oncol. 2010 Oct 20;28(30):4621–4629.
   PubMed Web of Science ®Google Scholar
• Kumar SK, Dispenzieri A, Lacy MQ, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 2014 May;28(5):1122–1128.
   PubMed Web of Science ®Google Scholar
• Cavo M, Tacchetti P, Patriarca F, et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet. 2010 Dec 18;376(9758):2075–2085.
   PubMed Web of Science ®Google Scholar
• Durie B, Hoering A, Rajkumar SV, et al. Bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate Autologous Stem Cell Transplant (ASCT): results of the randomized phase III trial SWOG S0777. Blood. 2015 Dec 3;126(23):25.
   PubMedGoogle Scholar
• D’Agostino M, De Paoli L, Conticello C, et al. Continuous therapy in standard- and high-risk newly-diagnosed multiple myeloma: A pooled analysis of 2 phase III trials. Crit Rev Oncol Hematol. 2018;132:9–16.
   PubMed Web of Science ®Google Scholar